We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Acadia Submits Nuplazid NDA for Parkinson’s Psychosis
Acadia Submits Nuplazid NDA for Parkinson’s Psychosis
Acadia Pharmaceuticals Wednesday filed an NDA with the FDA for Nuplazid, a product that, if approved, would be a first-in-class drug and the first specific treatment for Parkinson’s disease psychosis.